Result Update:Arvind SmartSp.
Axis Direct
With a 34% upside from the CMP, we maintain our long-term BUY rating on the stock.
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
31 Jan 2025 | Arvind SmartSpaces |
Axis Direct
|
668.15 | 1005.00 | 795.75 (-16.04%) | 50.42 |
Buy
|
||||
01 Feb 2025 | Karnataka Bank |
Edelweiss
|
208.50 | 310.00 | 182.50 (14.25%) | 48.68 |
Buy
|
||||
29 Jan 2025 | JSW Energy |
Axis Direct
|
524.05 | 770.00 | 474.75 (10.38%) | 46.93 |
Buy
|
||||
21 Jan 2025 | Cyient DLM |
Motilal Oswal
|
472.45 | 700.00 | 596.10 (-20.74%) | 48.16 |
Buy
|
Slowdown in order flows dampens growth visibility
Motilal Oswal
Cyient DLM’s (CYIENTDL) 3QFY25 consolidated revenue/EBITDA grew by ~38%/23% YoY. However, EBITDA missed our estimates as margins declined 90bp YoY due to a high mix of low-margin business (BEL order execution)
|
|||
09 Jan 2025 | PVR INOX |
Geojit BNP Paribas
|
971.85 | 1437.00 | 1161.60 (-16.34%) | 47.86 |
Buy
|
||||
11 Feb 2025 | Apeejay Surrendra |
IDBI Capital
|
163.38 | 245.00 | 172.31 (-5.18%) | 49.96 |
Buy
|
||||
10 Feb 2025 | REC |
Emkay
|
404.80 | 600.00 | 423.45 (-4.40%) | 48.22 |
Buy
|
Enough fuel to power growth, profitability; attractive valuation
Emkay
REC reported a satisfactory quarter in terms of margins, credit cost, and asset quality, while growth in Q3 was a tad below expectations on account of higher repayment and resolution of NPAs; however, disbursement remained strong.
|
|||
24 Mar 2025 | Praj Industries |
Prabhudas Lilladhar
|
503.65 | 751.00 | 581.55 (-13.40%) | 49.11 |
Buy
|
Praj Industries (PRJ IN) Management Meet Update GenX...
Prabhudas Lilladhar
We met with the management of Praj Industries at a conference, where they provided insights into the progress of Praj's GenX facility and the growth prospects across its business verticals. The orders for the GenX facility are anticipated from Q1FY26 while the facility is expected to contribute peak revenue of ~Rs10-25bn per annum. Challenges persist in the CBG sector due to concerns over operational and economic viability. However, Praj remains confident in its prospects, supported by its multi-feedstock technology. The potential imposition of reciprocal tariffs by the U.S. is not expected to have a...
|
|||
13 Jan 2025 | Medplus Health |
Keynote Capitals Ltd
|
899.95 | 1340.00 | 815.40 (10.37%) | 48.90 |
Buy
|
||||
24 Mar 2025 | Varun Beverages |
Motilal Oswal
|
462.10 | 680.00 | 531.10 (-12.99%) | 47.15 |
Buy
|
||||
more
loading
|